ライフサイエンスコーパス: interleukin-10

1 tokines (transforming growth factor beta and interleukin 10).

2 -1, B-cell activating factor, interleukin-6, interleukin-10).

3 d inflammation (tumor necrosis factor-alpha, interleukin-10).

4 m-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.

5 osis factor alpha, surfactant protein D, and interleukin-10.

6 FNgamma and TLR4 signaling, and secretion of interleukin-10.

7 derline significant inverse correlation with interleukin-10.

8 erleukin-6, tumor necrosis factor-alpha, and interleukin-10.

9 retion of protective immunomodulatory factor interleukin-10.

10 air levels of the immunosuppressive cytokine interleukin-10.

11 in-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001).

12 tor-alpha (+66%) and decreased production of interleukin-10 (-23%) by monocytes of sepsis patients.

13 ukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001).

14 In the absence of interleukin-10, a component of the regulatory immune res

15 hydrocortisone decreased the blood level of interleukin-10, a cytokine centrally involved in the reg

16 hibitors of NF-kappaB pathway, as well as by Interleukin-10, a known anti-inflammatory cytokine.

17 Gene expression of interleukin-10, an immune-modulatory cytokine, was signi

18 eukin 4, and M2-associated anti-inflammatory interleukin 10 and arginase I.

19 anti-SLAMF4 and anti-CD3 increased levels of interleukin 10 and interferon gamma secretion by IEL, co

20 (Tregs) and the immunosuppressive cytokines interleukin 10 and transforming growth factor beta is st

21 produce the anti-inflammatory mediators IL (interleukin)-10 and TGF-beta1, and the angiogenic growth

22 rotective effect required host production of interleukin-10 and host Tregs.

23 ry human tissues, activate anti-inflammatory interleukin-10 and improve colitis symptoms in a colitis

24 od-stage specific CD4(+) T cells coproducing interleukin-10 and interferon gamma (P = .001), which we

25 d set of traits, including a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent

26 for inducible protein-10 in driving systemic interleukin-10 and morbidity and highlighting the potent

27 tly increased the anti-inflammatory cytokine interleukin-10 and reduced proinflammatory cytokines, ty

28 l suppression was attributed to a release of interleukin-10 and S100A12 and increased PD-L1 expressio

29 e is a turtle herpesvirus, (iii) it contains interleukin-10 and semaphorin genes (the first time thes

30 also revealed viral counterparts of cellular interleukin-10 and semaphorin, which have not been descr

31 orin, macrophage inflammatory protein 1beta, interleukin 10, and CD107a) in CD8 T cells.

32 necrosis factor alpha, interleukin 6 (IL-6), interleukin 10, and lipopolysaccharide binding protein w

33 w defective production of interleukin 1beta, interleukin 10, and monocyte chemoattractant protein 1 i

34 Tumor necrosis factor alpha, interleukin 10, and the expression of miR-155 and miR-10

35 interferon gamma (IFN-gamma), interleukin 2, interleukin 10, and tumor necrosis factor alpha (TNF-alp

36 rleukin 1beta, interleukin 6, interleukin 8, interleukin 10, and tumor necrosis factor alpha release

37 xpress programmed death ligand 1 (PD-L1) and interleukin-10, and directly suppress liver cytotoxic CD

38 consisting of interleukin-6, interleukin-8, interleukin-10, and fractalkine was identified to be the

39 ly loaded with interleukin-6, interleukin-8, interleukin-10, and fractalkine, was significantly highe

40 interleukin-6, tumor necrosis factor alpha, interleukin-10, and interferon-gamma in acute disease.

41 ignificant increase in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist po

42 rculatory suppressive factors arginase-1 and interleukin-10, and lower total antioxidant capacity.

43 ion of pericentrin attenuated interleukin-6, interleukin-10, and MCP1 secretion, suggesting that the

44 related with decreased expression of CTLA-4, interleukin-10, and transforming growth factor-beta.

45 hey secrete interferon-gamma, interleukin-2, interleukin-10, and tumor necrosis factor.

46 and 3) selective secretion of interleukin-6, interleukin-10, and vascular endothelial growth factor t

47 changes in interleukin-6, interleukin-8, and interleukin-10 blood levels.

48 Cs, which was dependent on the generation of interleukin 10 by Tregs.

49 ation markers, such as YM-1, arginase-1, and interleukin-10 by activation of mer receptor tyrosine ki

50 erleukin-6, tumor necrosis factor-alpha, and interleukin-10 by lipopolysaccharide-stimulated leukocyt

51 egulatory B-cell-associated surface markers, interleukin-10, chemokine receptors, and immunoglobulin

52 ue of the cellular immunomodulatory cytokine interleukin 10 (cIL-10), which, due to alternative splic

53 tokines that are orthologs of human cellular interleukin 10 (cIL-10).

54 Both cytomegalovirus interleukin 10 (cmvIL-10) and Latency-associated cytomeg

55 UL111A encodes cytomegalovirus-encoded human interleukin-10 (cmvIL-10), a homolog of the potent immun

56 solvers" had high levels of G-CSF, CCL2, and interleukin-10 compared with the "hypothermic" group whe

57 repeatedly measured plasma interleukin-6 and interleukin-10 concentrations using cytometric bead arra

58 cytokine concentrations, whereas increasing interleukin-10 concentrations.

59 individual cytokines showed that exposure to interleukin 10 could replicate this effect.

60 application, secreting human proinsulin and interleukin-10, cured 66% of mice with new-onset diabete

61 ctive: To determine the mechanisms of IL-10 (interleukin-10) deficient-EPC-derived exosome dysfunctio

62 um induces pancolitis in colitis-susceptible interleukin-10-deficient mice and this phenotype require

63 lonized germfree wild-type and colitis-prone interleukin-10-deficient mice with defined bacterial con

64 accelerated onset of experimental colitis in interleukin-10-deficient mice, altered bacterial composi

65 ion, splenic natural killer cells induced an interleukin-10-dependent elimination of splenic dendriti

66 ammatory interleukin-6 and anti-inflammatory interleukin-10 during three distinct time periods after

67 ecrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leu

68 nin also triggered anti-inflammatory factors interleukin-10, heme oxygenase-1, and Hsp70 in macrophag

69 f the potent immunomodulatory cytokine human interleukin 10 (hIL-10).

70 f the potent immunomodulatory cytokine human interleukin 10 (hIL-10).

71 Individually, log10 mean concentrations of interleukin 10 (IL-10) and CXCL10 were significantly hig

72 ated by fluorescence-activated cell sorting; interleukin 10 (IL-10) and IL-18 and soluble FAS ligand

73 ded early increases in Th2 cytokines such as interleukin 10 (IL-10) and IL-5 and late-stage increases

74 rus-specific T cells, elevated production of interleukin 10 (IL-10) and programmed death-1 (PD-1) the

75 killed spherules [FKS]) and for secretion of interleukin 10 (IL-10) and proinflammatory cytokines in

76 ced smaller amounts of the immunosuppressive interleukin 10 (IL-10) and transforming growth factor be

77 Furthermore, the expression of interleukin 10 (IL-10) at the RNA and protein levels was

78 We found that interleukin 10 (IL-10) derived from CD4(+) regulatory T

79 harmacologic or genetic approaches inhibited interleukin 10 (IL-10) expression and increased expressi

80 o be a potent inducer of human and murine DC interleukin 10 (IL-10) in vitro, a cellular event that w

81 Interleukin 10 (IL-10) is an anti-inflammatory cytokine

82 Interleukin 10 (IL-10) is an anti-inflammatory cytokine

83 Interleukin 10 (IL-10) is an antiinflammatory cytokine,

84 l coma score was associated with an elevated interleukin 10 (IL-10) level in serum specimens from HSV

85 erleukin 8, tumor necrosis factor alpha, and interleukin 10 (IL-10) production in 20 HIV-infected pat

86 Cell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aure

87 n gamma, interleukin 1beta, CCL5/RANTES, and interleukin 10 (IL-10) were elevated in RSV+ bronchiolit

88 ly, levels of the anti-inflammatory cytokine interleukin 10 (IL-10) were markedly elevated in monocyt

89 eukocytes, gamma interferon (IFN-gamma), and interleukin 10 (IL-10) were significantly reduced in inf

90 sulting from S1PR1 inhibition were driven by interleukin 10 (IL-10), a potent neuroprotective and ant

91 mor necrosis factor-alpha, interferon-gamma, interleukin 10 (IL-10), and CXCL9.

92 expression of the anti-inflammatory cytokine interleukin 10 (IL-10), and decreasing that of the pro-i

93 IL-6, interferon gamma (IFN-gamma), interleukin 10 (IL-10), and gp120 levels were quantified

94 ess interferon gamma, more neutrophils, more interleukin 10 (IL-10), and increased M. tuberculosis nu

95 erleukin1beta, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14 compared with H

96 roduce anti-inflammatory cytokines including interleukin 10 (IL-10), IL-35 and transforming growth fa

97 gland sonicate showed elevated production of interleukin 10 (IL-10), interleukin 13, interferon gamma

98 interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 22 (IL-22), and tumo

99 ted individuals, induced protein 10 (IP-10), interleukin 10 (IL-10), macrophage inflammatory protein

100 (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha, and

101 st the hypothesis that constitutive level of interleukin 10 (IL-10), which may be high in elderly sub

102 The frequencies of FoxP3+ CD4+ T cells and interleukin 10 (IL-10)-expressing CD4+ T cells were incr

103 Interleukin 10 (IL-10)-producing B cells (regulatory B c

104 The great majority of interleukin 10 (IL-10)-producing CD4(+) T cells were Fox

105 ion of the potent anti-inflammatory cytokine interleukin 10 (IL-10).

106 plasma levels of anti-inflammatory cytokine interleukin 10 (IL-10).

107 2019 (COVID-19) is the dramatic elevation of interleukin 10 (IL-10).

108 d activator whose expression is repressed by interleukin 10 (IL-10).

109 eg cells to produce the suppressive cytokine interleukin 10 (IL-10).

110 oxide production, and elevated synthesis of interleukin 10 (IL-10).

111 production of the immunosuppressive cytokine interleukin 10 (IL-10).

112 tensity of interleukin 4 (IL-4; P < .05) and interleukin 10 (IL-10; 1440 vs 1273; P < .05).

113 These cells produce interleukin-10 (IL-10) and accumulate mitochondrial reac

114 tozoan parasite Leishmania mexicana requires interleukin-10 (IL-10) and FcgammaRIII (an activating Ig

115 gnant compared to nonpregnant women with CL, interleukin-10 (IL-10) and IL-4 expression were approxim

116 ther immunosuppressive pathways, such as the interleukin-10 (IL-10) and programmed death 1 (PD-1) pat

117 n response to the immune regulatory cytokine interleukin-10 (IL-10) and regulatory T cells.

118 cal source of the anti-inflammatory cytokine interleukin-10 (IL-10) and the metalloproteinase MMP9.

119 tive transfer into mice; they also increased interleukin-10 (IL-10) and transforming growth factor-be

120 Treatment of donor corneas with interleukin-10 (IL-10) and transforming growth factor-be

121 hibition of MIP-2 and KC expression involved interleukin-10 (IL-10) and, to a lesser extent, IL-4 and

122 Here, we explored the role of the interleukin-10 (IL-10) axis in restoring murine microgli

123 Interleukin-1b (IL-1b) and interleukin-10 (IL-10) biomarkers are one of many antige

124 s (twice in relation to control animals) and interleukin-10 (IL-10) concentrations in tissue in the i

125 Interleukin-10 (IL-10) curtails immune responses to micr

126 ved suppressor cells, the immune-suppressive interleukin-10 (IL-10) cytokine, and the down-modulatory

127 bitory signals, including increased PD-1 and interleukin-10 (IL-10) expression by cytotoxic T cells i

128 N2)-p105 complex to induce the expression of interleukin-10 (IL-10) for viral pathogenesis.

129 ibitor demonstrate a significant increase of interleukin-10 (IL-10) gene expression, which indicates

130 Interleukin-10 (IL-10) has been implicated in susceptibi

131 Although gamma interferon (IFN-gamma) and interleukin-10 (IL-10) have been shown to be critically

132 sts a role for the immunomodulatory cytokine interleukin-10 (IL-10) in hepatitis C virus (HCV)-specif

133 wing that B1a cells secreted a high level of interleukin-10 (IL-10) in response to C. burnetii infect

134 producers of the anti-inflammatory cytokine interleukin-10 (IL-10) in the intestine, thus playing an

135 Interleukin-10 (IL-10) is a dimeric cytokine with both i

136 Interleukin-10 (IL-10) is a key immunoregulatory cytokin

137 Interleukin-10 (IL-10) is a pleiotropic anti-inflammator

138 Interleukin-10 (IL-10) is an immunomodulatory cytokine t

139 ial survival in vivo and reduced gallbladder interleukin-10 (IL-10) levels.

140 that rhesus macaques immunized against viral interleukin-10 (IL-10) manifest delayed rhesus cytomegal

141 lls producing the anti-inflammatory cytokine interleukin-10 (IL-10) modulates the clearance of CKRP-S

142 ion, while alternative activation of MDMs by interleukin-10 (IL-10) or LPS-plus-IL-1beta treatment si

143 es inhibitory networks, such as the PD-1 and interleukin-10 (IL-10) pathways, that impair immunity an

144 Interleukin-10 (IL-10) plays an important role in the su

145 stemic reinfection is associated with robust interleukin-10 (IL-10) production and impaired protectiv

146 Interleukin-10 (IL-10) production and the percentage of

147 t triggered higher inflammatory cytokine and interleukin-10 (IL-10) production, a delayed gammadelta

148 differentiation to plasma cells, as well as interleukin-10 (IL-10) production, both of which are dep

149 athways, which subsequently led to a reduced interleukin-10 (IL-10) production.

150 owever, the deletion clones are deficient in interleukin-10 (IL-10) production.

151 creened the gamma interferon (IFN-gamma) and interleukin-10 (IL-10) responses to 6 HCMV peptide pools

152 significant neutrophil recruitment and early interleukin-10 (IL-10) responses, suggesting that the re

153 Purpose Interleukin-10 (IL-10) stimulates the expansion and cyto

154 ascular endothelial growth factor (VEGF) and interleukin-10 (IL-10) than MSCs homing to non-pFUS-trea

155 001) and significantly lower serum levels of interleukin-10 (IL-10) than patients with MRSA bacteremi

156 patients induces a rapid increase in plasma interleukin-10 (IL-10) to levels that are significantly

157 ound that adipose tissue macrophages produce interleukin-10 (IL-10) upon feeding, which suppresses he

158 production of the anti-inflammatory cytokine interleukin-10 (IL-10) via the activation of the transcr

159 the levels of regulatory T cells (Tregs) and interleukin-10 (IL-10) were elevated at the end of the e

160 ates inflammation, the beneficial effects of interleukin-10 (IL-10) were further examined in leptin-d

161 We have previously shown that expression of Interleukin-10 (IL-10), a classical anti-inflammatory cy

162 inhibits the induction of anti-inflammatory interleukin-10 (IL-10), a phenotype effectively reversed

163 The biological function of interleukin-10 (IL-10), a pleiotropic cytokine with an e

164 igh concentrations of lung tissue-associated interleukin-10 (IL-10), an anti-inflammatory and immunos

165 Interleukin-10 (IL-10), an important immunomodulatory cy

166 nterferon (IFN-gamma), interleukin-6 (IL-6), interleukin-10 (IL-10), and complement factor H was unaf

167 e secretion of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), and transforming growth factor-b

168 okines, such as tumor necrosis factor alpha, interleukin-10 (IL-10), IL-12, IL-1alpha, IL-6, and IL-1

169 We found elevated levels of interleukin-10 (IL-10), IL-1beta, chemokine ligand 2 (CC

170 Through the production of interleukin-10 (IL-10), IL-35, and transforming growth f

171 ines including interferon-gamma (IFN-gamma), interleukin-10 (IL-10), IL-6, and IL-1 are produced in r

172 Increasing evidence demonstrates that interleukin-10 (IL-10), known as an immunosuppressive cy

173 tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10), two cytokines strongly implicate

174 demand hematopoiesis in part by induction of interleukin-10 (IL-10)- and IL-27-mediated mechanisms.

175 Immune-mediated pathology in interleukin-10 (IL-10)-deficient mice during blood-stage

176 2s in this process and instead discovered an interleukin-10 (IL-10)-dependent cellular crosstalk in t

177 enous replacement therapy induced a complex, interleukin-10 (IL-10)-dependent, antigen-specific syste

178 Interleukin-10 (IL-10)-producing B cells (B10 cells) pla

179 We hypothesized that naturally occurring, interleukin-10 (IL-10)-producing Bregs maintain toleranc

180 Interleukin-10 (IL-10)-producing regulatory B (Breg) cel

181 sorders has identified a functional group of interleukin-10 (IL-10)-producing regulatory B cells (Bre

182 a significant increase of the expression of interleukin-10 (IL-10).

183 production of the anti-inflammatory cytokine interleukin-10 (IL-10).

184 ls to secrete the anti-inflammatory cytokine interleukin-10 (IL-10).

185 xcessive immune responses via the release of interleukin-10 (IL-10).

186 IL-1beta) and the immunosuppressive cytokine interleukin-10 (IL-10).

187 ing levels of the anti-inflammatory cytokine interleukin-10 (IL-10).

188 expression of the anti-inflammatory cytokine interleukin-10 (IL-10).

189 ered via the local and sustained delivery of interleukin-10 (IL-10; anti-inflammatory) and anti-trans

190 and chemokine (gamma interferon [IFN-gamma], interleukin 10 [IL-10], IL-13, IL-6, granulocyte-macroph

191 (tumor necrosis factor alpha [TNF-alpha] and interleukin-10 [IL-10]), BMMs were transfected with sele

192 nical malaria (gamma interferon [IFN-gamma], interleukin-10 [IL-10], and tumor necrosis factor alpha

193 cell (Treg) percentages; and interleukin 6, interleukin 10, IL-17A, interleukin 22, interleukin 23,

194 Exposure of Interleukin 10 (il10)-deficient mice to cigarette smoke

195 Models of interleukin-10 (Il10) and matrix metalloproteinase 8 (Mm

196 Interleukin-10 (IL10) overproduction (P = .0003) was fou

197 We have previously shown that interleukin-10 (IL10) suppresses pressure overload-induc

198 of the cardinal anti-inflammatory cytokine, interleukin-10 (IL10).

199 of the rhesus cytomegalovirus-encoded viral interleukin-10 immune-modulating protein.

200 his work, we showed that the main sources of interleukin 10 in peripheral blood mononuclear cells (PB

201 ministered lentiviral vector encoding murine interleukin-10 in altering the onset and relapse of dext

202 the anti-inflammatory markers arginase 1 and interleukin-10 in murine BMDMs.

203 ature" comprising interferon (IFN)-gamma and interleukin-10 in T1D patients and IFN-gamma in siblings

204 65370-575 and the anti-inflammatory cytokine interleukin-10 in the gut.

205 2.24 reduced the production of TNF-alpha and interleukin-10, inhibited phagocytic activity and stimul

206 response as modelled by an interleukin-6 and interleukin-10 interaction term was not (relative risk,

207 her in ZIKV-infected patients, and levels of interleukin 10, interferon gamma-induced protein 10 (IP-

208 otential control of HIV infection, including interleukin 10, interleukin 13, and interleukin 22.

209 interleukin-5, interleukin-6, interleukin-9, interleukin-10, interleukin-12, interleukin-13, tumor ne

210 (tumor necrosis factor-alpha, interleukin-6, interleukin-10, interleukin-12, interleukin-17) at day 1

211 controls n = 16) displayed reduced levels of interleukin-10, interleukin-12p40, interferon-gamma and

212 leukin-1alpha, interleukin-6, interleukin-8, interleukin-10, interleukin-15, eotaxin-3, interferon ga

213 leukin-8/CCL8) and cytokines (interleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage c

214 rleukin-1beta, interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis facto

215 Interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis facto

216 twork suggested that post-spinal cord injury interleukin-10 is driven by inducible protein-10, wherea

217 expression of the anti-inflammatory cytokine interleukin 10, it did not strongly contribute to the ab

218 L-10) and Latency-associated cytomegalovirus interleukin 10 (LAcmvIL-10) (collectively vIL-10) are ex

219 beta and interferon gamma levels, and higher interleukin 10 levels than PFCE-air-treated HbSS mice.

220 rrelated positively with Leishmania-specific interleukin 10 levels, negatively with Leishmania-specif

221 ; increased serum interleukin 6, CXCL10, and interleukin 10 levels; increased neutrophil counts; and

222 erleukin-6, tumor necrosis factor-alpha, and interleukin-10 levels in vivo.

223 Interleukin-6 and interleukin-10 levels were both independently associated

224 In addition, there was an increase in interleukin-10 levels with RvD1 therapy in both mice wit

225 feron-gamma, CXCL12, XCL1, interleukin-6 and interleukin-10 levels.

226 dependent response and favoring a macrophage interleukin-10-like phenotype.

227 mice with muscle-specific overexpression of interleukin-10 (M(IL10)).

228 al lesion, whereas a robust monocyte-derived interleukin 10-mediated profile is observed in children

229 ighted the role of the type I interferon and interleukin 10-mediated responses.

230 Interleukin-10-mediated regenerative postnatal tissue re

231 mainly produced by CD4(+)CD25(-) cells, and interleukin 10 messenger RNA expression was associated w

232 rs with human AAT resulted in an increase in interleukin-10 messenger RNA and CD8(+)CD11c(+)CD205(+)

233 -gamma, whereas most healthy donors produced interleukin-10 only.

234 ed positive for tumor necrosis factor alpha, interleukin 10, or interleukin 6 production by HBV surfa

235 ntercellular adhesion molecule-1 (P < .001), interleukin-10 (P = .041), monocyte chemotactic protein-

236 eron-gamma elevation (P < .001) and possibly interleukin-10 (P = .07) were associated with toxicity.

237 r-alpha, p = 0.003; interleukin-6, p = 0.01; interleukin-10, p = 0.005), and acute kidney injury when

238 matory (interleukin-8) to anti-inflammatory (interleukin-10) plasma cytokine levels was greater in pa

239 evels of specific gamma interferon-positive, interleukin-10-positive T cells, which protect animals f

240 oantibody-positive) and partially regulated (interleukin-10-positive, pauci-autoantibody-positive) re

241 CL had increased frequencies of circulating interleukin 10-producing CD4(+)CD25(-)CD127(-/low) cells

242 of interferon gamma, reduced the numbers of interleukin 10-producing T cells, and increased neutroph

243 on, patients with AAH had greater numbers of interleukin 10-producing T cells, and reduced levels of

244 sion of naturally occurring Foxp3(+) CD25(+) interleukin-10-producing antigen-specific regulatory T c

245 ed lymphocytes were generated by coculturing interleukin-10-producing dendritic cells obtained from h

246 arrying the TLR1 80R-allele showed increased interleukin 10 production with C. burnetii exposure.

247 tibility to Leishmania infection, mainly via interleukin 10 production.

248 An increase of interleukin-10 production and the increase of a cell exh

249 ion, which was associated with a decrease in interleukin-10 production by hepatic T cells and a more

250 C resulted in higher interleukin-6 and lower interleukin-10 production by lipopolysaccharide-stimulat

251 cutaneous inflammatory responses induces of interleukin-10 production in dendritic cells and priming

252 d interleukin-17 production and decreases in interleukin-10 production that were not evident among sp

253 mor necrosis factor-alpha, nitric oxide, and interleukin-10 production.

254 lated M1 polarization through stimulation of interleukin-10 production.

255 Although both interleukin-6 and interleukin-10 productions are associated with death, th

256 eline [interleukin-6] and [interleukin-6] x [interleukin-10] profiles, whereas patients with the lowe

257 and interferon gamma (r = 0.562, P = .005), interleukin 10 (r = 0.453, P = .03), and sCD27 secretion

258 C-reactive protein (r = -0.70, P = 0.0006), interleukin-10 (r = -0.59, P = 0.007), and interleukin-6

259 The interleukin-6/interleukin-10 ratio directly correlated with plasma lac

260 ange complexes and a lower interleukin-1beta/interleukin-10 ratio than the control group (P < 0.05).

261 Infants with defects in the interleukin 10 receptor (IL10R) develop very early onset

262 SELEX experiment developing aptamers against Interleukin 10 receptor alpha chain (IL-10RA) and experi

263 Interleukin 6, interleukin 10 receptor alpha subunit, colony stimulatin

264 ncluding transforming growth factor beta and interleukin 10 receptor, were suppressed in low-ENL excr

265 Interleukin-10 receptor (IL-10R) signaling is considered

266 Intact interleukin-10 receptor (IL-10R) signaling on effector a

267 ges, stimulated M1 macrophage activation and interleukin 10 release, and decreased tumor necrosis fac

268 ot affecting tumor necrosis factor-alpha and interleukin-10 release).

269 6 hours but had normalized by day 2, whereas interleukin-10 remained persistently elevated and high-d

270 For TLR1, increased interleukin 10 responses to C. burnetii in individuals c

271 T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequenc

272 ntiviral vector-mediated local expression of interleukin-10 resulted in significantly increased level

273 s (CD4+, CD25+, and FoxP3+) and its cytokine interleukin 10, resulting in downregulation of T effecto

274 ically-delivered lentiviral vectors encoding interleukin-10 safely penetrated local mucosal tissue an

275 persist due to upregulation of the cellular interleukin-10 signaling pathway.

276 We found that levels of interleukin-6 and interleukin-10, specific markers of cardiac remodeling (

277 perfusion benefits, and increased levels of interleukin-10, suggestive of an anti-inflammatory effec

278 ediated boosting of antibody titers to viral interleukin-10, there was modest evidence for increased

279 founding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours

280 Sustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours

281 ation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) p

282 ed expression of mannose receptor-1 (CD206), interleukin-10, transforming growth factor-beta, arginas

283 Moreover, we identified interleukin-10-triggered activation of transcription fac

284 omarkers (C-reactive protein, interleukin 6, interleukin 10, tumor necrosis factor alpha), and the me

285 here is accumulating evidence that the viral interleukin-10 (vIL-10) ortholog of both human and rhesu

286 Also, in CL lesions, interleukin 10 was mainly produced by CD4(+)CD25(-) cell

287 that the parasite-driven regulatory cytokine interleukin-10 was exclusively coming from the intermedi

288 Circulating interleukin-10 was significantly elevated in thoracocerv

289 ther with production of interferon gamma and interleukin 10, was also detected in the lesions.

290 Plasma levels of interleukin-6 and interleukin-10 were 290 and 166 pg/mL and decreased at a

291 levels of the key antiinflammatory cytokine interleukin-10 were attenuated (-40%; p = 0.003).

292 eukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorb

293 or necrosis factor-alpha, interleukin-6, and interleukin-10 were observed 5 hours after cecal ligatio

294 Increased levels of interleukin-8 and interleukin-10 were observed in children with Down syndr

295 necrosis factor alpha, gamma interferon, and interleukin-10 were upregulated in infected mice.

296 s, as well as an anti-inflammatory cytokine (interleukin-10), were reduced in the lungs of vaccinated

297 tokines (C-X-C motif chemokine ligand 10 and interleukin 10), which correlated with populations of in

298 uced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target gen

299 production of the anti-inflammatory cytokine interleukin 10 while inhibiting B-cell expression of pro

300 specific CD4(+) T-cells in children produced interleukin 10, while responses in adults were dominated